These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 17383057

  • 1. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
    Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R, Family Medicine Group of Pianiga.
    Vaccine; 2007 May 16; 25(20):3955-61. PubMed ID: 17383057
    [Abstract] [Full Text] [Related]

  • 2. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly].
    Li RC, Fang HH, Li YP, Liu YP, Nong Y, Huang GB.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun 16; 29(6):548-51. PubMed ID: 19040034
    [Abstract] [Full Text] [Related]

  • 3. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
    Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M.
    Vaccine; 2009 Oct 23; 27(45):6291-5. PubMed ID: 19840662
    [Abstract] [Full Text] [Related]

  • 4. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
    Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, Podda A.
    Pediatr Infect Dis J; 2009 Jul 23; 28(7):563-71. PubMed ID: 19561422
    [Abstract] [Full Text] [Related]

  • 5. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
    Sindoni D, La Fauci V, Squeri R, Cannavò G, Bacilieri S, Panatto D, Gasparini R, Amicizia D.
    J Prev Med Hyg; 2009 Jun 23; 50(2):121-6. PubMed ID: 20099444
    [Abstract] [Full Text] [Related]

  • 6. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.
    O'Hagan DT.
    Expert Rev Vaccines; 2007 Oct 23; 6(5):699-710. PubMed ID: 17931151
    [Abstract] [Full Text] [Related]

  • 7. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly.
    Ruf BR, Colberg K, Frick M, Preusche A.
    Infection; 2004 Aug 23; 32(4):191-8. PubMed ID: 15293073
    [Abstract] [Full Text] [Related]

  • 8. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV, Scaramuzza A, Riboni S, Mameli C, Pariani E, Tanzi E, Zanetti A, Radaelli G.
    Vaccine; 2009 Aug 27; 27(39):5357-62. PubMed ID: 19607951
    [Abstract] [Full Text] [Related]

  • 9. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.
    Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB.
    Clin Infect Dis; 2006 Nov 01; 43(9):1135-42. PubMed ID: 17029131
    [Abstract] [Full Text] [Related]

  • 10. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.
    de Bruijn I, Meyer I, Gerez L, Nauta J, Giezeman K, Palache B.
    Vaccine; 2007 Dec 21; 26(1):119-27. PubMed ID: 18063446
    [Abstract] [Full Text] [Related]

  • 11. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses.
    Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, Montomoli E, Icardi G, Gasparini R, Crovari P.
    Vaccine; 2008 Mar 17; 26(12):1525-9. PubMed ID: 18294741
    [Abstract] [Full Text] [Related]

  • 12. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
    Dong PM, Li YQ, Zheng TZ, Jia YP, Li F, Han TW, Qiao RX, Zhang BH.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul 17; 24(7):570-3. PubMed ID: 12975010
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis.
    Dell'Era L, Corona F, Daleno C, Scala A, Principi N, Esposito S.
    Vaccine; 2012 Jan 20; 30(5):936-40. PubMed ID: 22138210
    [Abstract] [Full Text] [Related]

  • 14. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
    Lopez P, Caicedo Y, Sierra A, Tilman S, Banzhoff A, Clemens R.
    J Infect Dis; 2011 Jun 15; 203(12):1719-28. PubMed ID: 21606530
    [Abstract] [Full Text] [Related]

  • 15. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.
    Del Giudice G, Hilbert AK, Bugarini R, Minutello A, Popova O, Toneatto D, Schoendorf I, Borkowski A, Rappuoli R, Podda A.
    Vaccine; 2006 Apr 12; 24(16):3063-5. PubMed ID: 16464520
    [Abstract] [Full Text] [Related]

  • 16. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates.
    Ansaldi F, Zancolli M, Durando P, Montomoli E, Sticchi L, Del Giudice G, Icardi G.
    Vaccine; 2010 Jun 07; 28(25):4123-9. PubMed ID: 20433807
    [Abstract] [Full Text] [Related]

  • 17. Influenza vaccine with squalene adjuvant: new preparation. No better than available products.
    Prescrire Int; 2004 Dec 07; 13(74):206-8. PubMed ID: 15599987
    [Abstract] [Full Text] [Related]

  • 18. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.
    Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HK, Graham IL, Noah DL, He F, Hill H.
    J Infect Dis; 2008 Mar 01; 197(5):667-75. PubMed ID: 18260764
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly.
    Seo YB, Choi WS, Lee J, Song JY, Cheong HJ, Kim WJ.
    Clin Vaccine Immunol; 2014 Jul 01; 21(7):989-96. PubMed ID: 24828092
    [Abstract] [Full Text] [Related]

  • 20. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.
    El Sahly H.
    Expert Rev Vaccines; 2010 Oct 01; 9(10):1135-41. PubMed ID: 20923265
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.